UCB shares dip as investors worry forecast may be too optimistic despite Bimzelx sales beat

UCB reported that sales of its lead drug Bimzelx exceeded analysts' expectations for the quarter.

However, the company also gave a full-year revenue outlook that some investors view as overly optimistic.

The mixed signals led to a decline in UCB’s share price on Thursday, with the stock falling despite the positive sales number.